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Abstract
Background: The obesity paradox in COPD describes protective effects of obesity on lung pathology and
inflammation. However, the underlying relationships between obesity, diet and disease outcomes in COPD
are not fully understood. In this study we measured the response to dietary fatty acids upon markers of
inflammation and remodelling in human lung cells from people with and without COPD.
Methods: Pulmonary fibroblasts were challenged with ω-3 polyunsaturated fatty acids (PUFAs), ω-6 PUFAs,
saturated fatty acids (SFAs) or the obesity-associated cytokine TNFα. After 48–72 h release of the pro-
inflammatory cytokines interleukin (IL)-6 and CXCL8 was measured using ELISA and mRNA expression and
deposition of the extracellular matrix (ECM) proteins fibronectin, type I collagen, tenascin and perlecan were
measured using qPCR or ECM ELISA, respectively.
Results: Challenge with the ω-6 PUFA arachidonic acid (AA), but not ω-3 PUFAs or SFAs, resulted in increased IL-6 and
CXCL8 release from fibroblasts, however IL-6 and CXCL8 release was reduced in COPD (n = 19) compared to non-COPD
(n = 36). AA-induced cytokine release was partially mediated by downstream mediators of cyclooxygenase (COX)-2 in
both COPD and non-COPD. In comparison, TNFα-induced IL-6 and CXCL8 release was similar in COPD and non-COPD,
indicating a specific interaction of AA in COPD. In patients with or without COPD, regression analysis revealed
no relationship between BMI and cytokine release. In addition, AA, but not SFAs or ω-3 PUFAs reduced the
basal deposition of fibronectin, type I collagen, tenascin and perlecan into the ECM in COPD fibroblasts. In
non-COPD fibroblasts, AA-challenge decreased basal deposition of type I collagen and perlecan, but not fibronectin
and tenascin.
Conclusions: This study shows that AA has disease-specific effects on inflammation and ECM protein deposition. The
impaired response to AA in COPD might in part explain why obesity appears to have less detrimental effects in COPD,
compared to other lung diseases.
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Introduction
More than two billion people around the world are over-
weight or obese, classified by a body mass index (BMI)
greater than, or equal to, 25 or 30 kg/m2, respectively
[1]. This global obesity epidemic is associated with many
chronic diseases and recently, its role in lung disease, in-
cluding chronic obstructive pulmonary disease (COPD),
has received new interest. Obesity is becoming more
common in mild-to moderate COPD with a prevalence
that is generally higher than the general population [2–
4]. In the general population, obesity has a major nega-
tive impact on health outcomes. However paradoxically,
mild-to moderate obesity in moderate to severe COPD
is reported to have protective effects on survival, lung
function decline and exacerbations [5–8]. The under-
lying mechanisms of the protective effects of obesity in
COPD are currently poorly understood.
In COPD, structural changes to the airways, also
known as airway remodelling, occur. A characteristic
feature of airway remodelling is airway wall thickening,
which is due to an increase in connective tissue. In-
creased airway wall thickness is associated with frequent
exacerbations and symptoms of chronic bronchitis [9,
10]. Connective tissue is composed of scaffolding pro-
teins termed the extracellular matrix (ECM). Perlecan,
fibronectin, collagens and tenascin are ECM proteins
and their presence is associated with remodelling and/or
inflammation in the airways. Tenascin and fibronectin
have been shown to be increased in COPD [11]. Inter-
estingly, obesity has also been shown to affect airway re-
modelling, with BMI being negatively associated with
emphysema and positively associated with airway wall
thickness [12]. This finding corresponds with the ‘blue
bloater’ phenotype of obese COPD patients, who are
more likely to have more bronchitis and less emphysema
[9, 13]. Although the exact mechanisms that drive re-
modelling are still undefined, ongoing chronic inflamma-
tory processes are likely to contribute.
In COPD, airway inflammation is characterized by in-
creased numbers of neutrophils, macrophages, and CD8
+ −T lymphocytes, as well as increased levels of interleu-
kin (IL)-6 and CXCL8 in the airways [14, 15]. Neutro-
phils and CXCL8 levels, in particular, are associated with
COPD exacerbations [15–17]. Neutrophils are also
strongly implicated in causing chronic bronchitis and
the destruction of lung tissue in emphysema, through
the production of reactive oxygen metabolites and tissue
damaging enzymes [16]. Obesity itself is associated with
chronic systemic low-grade inflammation, with increased
levels of serum IL-6 and TNFα, produced by adipose tis-
sue [18, 19]. Epidemiological evidence suggests a role for
diet in the prevention and management of COPD. In-
creased intake of certain nutrients, such as vitamin E, D
and C and ω-3 polyunsaturated fatty acids (PUFAs) are
positively associated with lung function in the general
population [20, 21]. In addition, epidemiologic studies
have demonstrated that increased intake of these nutri-
ents is associated with a decreased risk of COPD devel-
opment [20]. These effects are thought to be the result
of anti-oxidant and anti-inflammatory properties of
these nutrients. Little is known about effects of the
Western diet in COPD. The Western diet contributes to
obesity, being high in energy from macronutrients, in-
cluding saturated fatty acids (SFAs) and ω-6 PUFAs.
These fatty acids are shown to affect inflammatory pro-
cesses and have predominantly been associated with
pro-inflammatory effects and negatively associated with
outcomes in other lung diseases such as asthma [22, 23].
However, the effects of these fatty acids in COPD have
not been investigated. ω-3 PUFAs and SFAs affect in-
flammation by modifying toll-like receptor 4 (TLR4) sig-
nalling, whereas ω-6 PUFAs affect inflammation through
TLR4-indepenent (independent) mechanisms [24].
A clear causal relation between obesity, diet and disease
outcomes in COPD is yet to be proven, but the available
data suggest a link between these factors and it is import-
ant to understand their effects on airway inflammation
and remodelling in COPD. Pulmonary fibroblasts are the
major structural cell of the airway and play a crucial role
in tissue homeostasis, the production of pro-inflammatory
cytokines and ECM proteins and, therefore, are likely to
contribute to airway inflammation and remodelling [25,
26]. This study investigated whether pulmonary fibroblasts
derived from COPD versus non-COPD patients differ in
their inflammatory response to dietary fatty acids (ω-6
PUFAs, ω-3 PUFAs and SFAs) and the obesity-associated
cytokine TNFα in vitro. Also, the effect of BMI on this re-
sponse was assessed. Secondly, this study investigated
whether dietary fatty acids affect the expression and de-
position of ECM proteins in fibroblasts.
Methods and materials
Subjects
Primary fibroblasts were isolated from the parenchyma
of lungs from patients undergoing lung transplantation
or lung resection for thoracic malignancies from a total
of n = 32 donors with COPD, and a total of n = 50 do-
nors with lung disease other than COPD. The diagnosis
of disease was made by thoracic physicians according to
current guidelines. Approval for all experiments with
human lung was provided by the Human Ethics Com-
mittees of the University of Sydney and the Sydney
South West Area Health Service. Table 1 shows a sum-
mary of the patient demographics.
Cell culture
Isolation of pulmonary fibroblasts was performed, as
previously described by Krimmer et al. (2013) [27]. Cells
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were seeded in 12-well plates at a density of 6.2 × 104
cells/mL in DMEM containing 5% fetal bovine serum
(FBS) and 1% antibiotic-antimycotic (Gibco, Grand Island,
New York, US). When the cells reached 80% confluency,
they were serum starved by incubation in DMEM (Gibco,
Grand Island, New York, US) supplemented with 0.1% bo-
vine serum albumin (BSA) (Sigma Aldrich, Castle Hill,
NSW, Australia) and 1% antibiotic-antimycotic for 24 h
prior to stimulation. All experiments were carried out
using fibroblasts between passage 2 and 6.
Preparation of BSA-conjugated fatty acids
Stock solutions of 0.5 M ω-3 PUFA (docosahexaenoic
acid (DHA)) and SFA (palmitic acid (PA)) and 0.3 M
ω-6 PUFA (arachidonic acid (AA)) (Sigma Aldrich)
were prepared in 100% EtOH and stored at-20 °C.
Working water-soluble solutions of 10 mM were gen-
erated by incubating the fatty acids in 10% endotoxin
and fatty acid-free BSA (Sigma Aldrich), as previously
described by Gupta et al. (2012) and Pillon et al.
(2012) [28, 29]. These solutions were further diluted
in cell culture medium to obtain final concentrations
of 10 and 100 μM. These concentrations are based
on physiological concentrations and other in vitro
studies [30–33].
Treatment of cells with dietary fatty acids and TNFα
Pulmonary fibroblasts from COPD and non-COPD pa-
tients were stimulated with 10 and/or 100 μM AA,
DHA, PA, or TNFα (1 ng/ml) or vehicle (EtOH/BSA/cell
culture medium) and compared to untreated controls.
All cells were incubated at 37 °C with 5% CO2 for 6, 9,
24, 48 or 72 h. Total RNA or cell-free supernatants were
collected and stored at − 20 °C until further analysis.
Treatment of cells with indomethacin, celecoxib and
dexamethasone
Pulmonary fibroblasts from COPD and non-COPD pa-
tients were treated with the non-selective cyclooxygen-
ase (COX)-inhibitor, indomethacin (1 μM), the COX-2
selective inhibitor, celecoxib (0.01-1 μM) or corticoster-
oid, dexamethasone (0.1-1 μM) (all Sigma-Aldrich) for
60 min prior to challenge with dietary fatty acids.
Determination of IL-6, CXCL8 and PGE2 levels
Levels of IL-6 and CXCL8 in cell culture supernatants
were measured using sandwich ELISA. The amount of
IL-6 release was assessed with optimized anti-IL-6 anti-
body pairs from BD pharmingen, BD, Franklin Lakes,
NJ. A specific kit for CXCL8 was purchased from R&D
Systems (Minneapolis, Minnesota, USA) and used ac-
cording to the manufacturer’s instructions. PGE2 levels
were measured by enzyme immunoassay according to
the manufacturer’s instructions (R&D systems).
Cytotoxicity assay
Cell toxicity was estimated using a lactate dehydrogenase
(LDH) assay according to the manufacturer’s instruc-
tions (Sigma-Aldrich).
Determination of COX-2, fibronectin, type I collagen and
tenascin mRNA expression
COX-2, fibronectin, type I collagen or tenascin mRNA
expression in treated and untreated cell cultures was
measured by quantitative PCR (qPCR). Total RNA was
purified using the ISOLATE II RNA Mini Kit and tran-
scribed into cDNA using the SensiFAST™ cDNA Synthe-
sis Kit (Bioline, Alexandria, Australia). Both kits were
used as per the manufacturer’s instructions. qPCR was
performed using the StepOne Plus detection system and
data were collected and analysed by StepOne software
Table 1 Summary of patient demographics
All patients n = 82
Non-COPD (n = 50) COPD (n = 32)
Characteristics Resection for thoracic malignancy
(n = 17)
End stage lung disease other than COPD
(n = 33)
Pathology – 1. IPF (n = 17) (51.5%)
2. Pulmonary hypertension (n = 4) (12.1%)
3. Eisenmenger’s syndrome (n = 2) (6.1%)
4. BOS (n = 2) (6.1%)
5. Bronchiectasis (n = 2) (6.1%)
6. Other (n = 6) (18.2%)
1. Emphysema or COPD (n = 28) (87.5%)
2. α1-antitrypsin deficiency (n = 4) (12.5%)
Sex (n) Female/Male 13/4 11/22 13/19
Mean age (years) (SD) 61.0 (9.7) 55.5 (13.4) 59.1 (8.7)









COPD Chronic obstructive pulmonary disease, IPF Idiopathic pulmonary fibrosis, BOS Bronchiolitis obliterans syndrome, unk data Unknown, SD Standard deviation,
BMI Body mass index
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(Applied Biosystems, Melbourne, Australia). Assays were
carried out in triplicate using a reaction mixture con-
taining the Bioline SensiFAST Probe Hi-ROX Master
Mix, primer for COX-2, fibronectin, type I collagen or
tenascin and the ubiquitously expressed ribosomal RNA
(18S rRNA) was used as a housekeeping gene. Relative
expression and quantification was performed using the
2ΔΔCT method.
Measurement of ECM protein deposition
Fibronectin, type I collagen, tenascin and perlecan de-
position into the ECM was measured by ECM ELISA
using optimised monoclonal mouse-anti human perlecan
(2 μg/ml) (ThermoFisher Scientific), type I collagen
(2 μg/ml)(Sigma-Aldrich), fibronectin (0.5 μg/ml)
(Merck, Bayswater, Australia) and tenascin (0.5 μg/ml)
(Sigma-Aldrich) antibodies as previously described by
Kuo et al. (2011) [34].
Statistical analysis
Statistical analysis was conducted using GraphPad Prism
version 7 software (GraphPad Software, San Diego, CA).
After testing for normal distribution and equal variance,
comparisons of the data were carried out by a paired
t-test or Analysis of variance (ANOVA) with repeated
measures followed by a Bonferroni post-test, where ap-
propriate. All data on bar graphs are presented as mean
± standard error of the mean (SEM), unless otherwise
specified. A probability (p) value of less than or equal to
0.05 was considered significant.
Results
Reduced arachidonic acid-induced cytokine release in
COPD versus non-COPD
To assess the inflammatory response to dietary fatty
acids in pulmonary fibroblasts from COPD versus
non-COPD patients, cells were treated with 10 and
100 μM of AA, DHA or PA for 48 h and CXCL8 and
IL-6 release was measured. Challenge with DHA or PA
did not induce cytokine release from fibroblasts from
both COPD and non-COPD patients (data not shown).
However, challenge with AA resulted in increased
CXCL8 and IL-6 release in both groups. Interestingly,
CXCL8 and IL-6 release was greater in the non-COPD
group (n = 36) compared to the COPD group (n = 19) (p
< 0.001) (Fig. 1a and b). The non-COPD group consists
of patients with non-smoking related end-stage lung dis-
eases such as pulmonary hypertension and idiopathic
pulmonary fibrosis, as well as cells from macroscopically
normal lung tissue obtained from resection surgery. As
it was possible that pulmonary fibroblasts from patients
with disease such as pulmonary hypertension and idio-
pathic pulmonary fibrosis had a differential response to
fibroblasts from macroscopically normal lung tissue we
investigated if they respond differently to AA. Fibro-
blasts derived from patients with non-smoking re-
lated end-stage lung disease (n = 24) and patients
who were going lung resection for thoracic malig-
nancies (n = 12) had similar AA-induced cytokine re-
lease (Additional file 1: Fig. S1). These results justify
combining these two groups in the non-COPD group
and indicate a disease-specific effect of COPD, rather
than an effect of smoking.
The response to arachidonic is partially mediated through
cyclooxygenase with no differences between COPD and
non-COPD
AA can act as a bio-active molecule, and is the precur-
sor that is metabolized by COX to produce prostaglan-
dins, including PGE2. Prostaglandins are known to play
a key role in the generation of inflammatory responses.
Since the response to AA is different in COPD versus
non-COPD, we next assessed whether AA-induced
cytokine release is prostaglandin-dependent and
whether there are differences in the effect of inhibition
of COX on AA-induced cytokine release. We measured
the release of PGE2 and found that PGE2 levels are in-
creased upon challenge with AA 100 μM in both COPD
(n = 11) and non-COPD (n = 12) fibroblasts, with no
differences between the two groups (Fig. 1c). The
non-selective COX-inhibitor indomethacin and the
COX-2 selective inhibitor, celecoxib at a concentration
of 1 μM both partially suppressed AA-induced IL-6 and
CXCL8 release. There were no differences in the per-
centage of inhibition of AA-induced cytokine release in
the COPD versus the non-COPD group at all concen-
trations of indomethacin or celecoxib used (Fig. 1d, e, f
and g). These results show that the response to AA in
fibroblasts is partially mediated through downstream
mediators of COX-2, and partially mediated through
COX-2 independent mechanisms.
Simular AA-induced COX-2 mRNA expression in COPD
and non-COPD
To assess whether differences in COX-2 expression
could explain the differential response to AA in COPD
and non-COPD fibroblasts, we measured COX-2 mRNA
expression upon challenge with AA. An AA-induced in-
crease in COX-2 mRNA expression was observed after
6 h with COX-2 mRNA expression being maximal at
24 h. There were no differences in COX2 mRNA expres-
sion between COPD (n = 5) and non-COPD (n = 5) fi-
broblasts at any time-point (Fig. 2), thereby further
confirming that differences in COX-2 expression is not
the mechanism by which the differential response to AA
occurs.
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Arachidonic acid does not cause cytotoxicity in COPD and
non-COPD fibroblasts
To investigate whether reduced viability is the cause of
the impaired response of COPD fibroblasts to AA, we
performed a lactate dehydrogenase (LDH) assay and
found that AA does not cause cytotoxicity in both
COPD (n = 7) and non-COPD (n = 9) fibroblasts (Fig. 3).
No differential response to TNFα in COPD versus
non-COPD
We also assessed the inflammatory response to TNFα,
which is a pro-inflammatory cytokine and known to be
elevated in obese individuals. TNFα induced IL-6 and
CXCL8 release from fibroblasts from COPD (n = 15) and
non-COPD patients (n = 27), but there was no difference
between the two groups (Fig. 4).
Dexamethasone suppresses AA-induced cytokine release
in COPD and non-COPD
We next investigated the effects of a steroid, dexametha-
sone. Steroids have beneficial effects in many inflamma-
tory diseases by exerting their anti-inflammatory effects
through inhibiting multiple signal transduction path-
ways. Dexamethasone (1 μM) almost fully suppressed
AA-induced IL-6 and CXCL8 release (Fig. 5) in both
groups. Dexamethasone at the lowest concentration of
0.001 μM caused 72% inhibition of AA-induced CXCL8
in the non-COPD cells, whilst only 47% inhibition
Fig. 1 Reduced cytokine release upon arachidonic acid challenge in COPD versus non-COPD. Pulmonary fibroblasts from COPD (n = 11–19) and
non-COPD patients (n = 12–36) were unstimulated (control) or challenged with ω-6 PUFA arachidonic acid (AA) in 0.1% BSA-DMEM (10 and
100 μM) for 48 h. Cell free supernatants were collected and CXCL8 (a), IL-6 (b) and PGE2 (c) release was measured using ELISA or enzyme
immunoassay. Other cells from COPD (n = 6–7) and non-COPD (n = 6–7) patients were pre-treated with indomethacin (1 μM) (d, e) or celecoxib
(0.01-1 μM) (f, g) for 60 min prior to challenge with AA (100 μM) in 0.1% BSA-DMEM for 48 h. Cell free supernatants were collected and CXCL8
(d, f) and IL-6 (e, g) release was measured using ELISA. Data are expressed as mean ± standard error of the mean (a-c) or as % of AA-induced
cytokine release ± standard error of the mean (d-g). Two-way ANOVA with Bonferroni post-hoc testing was used to determine statistical
significance. Significance is represented as *** (p < 0.001)
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occurred in the COPD cells, suggesting a reduced ster-
oid sensitivity in COPD versus non-COPD cells.
Body mass index does not affect the production of
inflammatory cytokines
Since BMI is associated with clinical outcomes in COPD,
we investigated if BMI affects the production of inflam-
matory cytokines upon challenge with AA (100 μM). We
found no associations between CXCL8 or IL-6 release
and BMI in either the non-COPD (n = 32) or the COPD
group (n = 18) (Fig. 6).
Arachidonic acid reduces basal ECM protein mRNA
expression and deposition
Since lung pathology is different in obese COPD com-
pared to non-obese COPD, we assessed whether chal-
lenge with dietary fatty acids leads to changes in the
expression and deposition of ECM proteins. Challenge
with AA (100 μM) resulted in significantly reduced fi-
bronectin and type I collagen mRNA expression com-
pared to constitutive levels (n = 5, p < 0.01) (Fig. 7a and
b) in COPD fibroblasts. There was no effect on TNC
mRNA expression (Fig. 7c). The effect of AA on fibro-
nectin mRNA expression was specific for COPD cells,
whereas AA also decreased basal expression of type I
Fig. 2 Similar arachidonic acid-induced COX-2 mRNA expression in COPD and non-COPD. Pulmonary fibroblasts from COPD (n = 5) and
non-COPD patients (n = 5) were unstimulated (control) or challenged with ω-6 PUFA arachidonic acid (AA) in 0.1% BSA-DMEM (100 μM)
for 6 (a), 9 (b), 24 (c) or 48 (d) hours. Total RNA was extracted and cyclooxygenase (COX)-2 mRNA expression was measured using qPCR.
The results are normalized to the endogenous control (18S rRNA), and presented as fold change from control (t = 0 h) ± standard error of
the mean. Unpaired t-test was used to determined statistical significance. There were no statistical differences
Fig. 3 Arachidonic acid does not cause cytotoxicity in COPD and
non-COPD fibroblasts. Pulmonary fibroblasts from COPD (n = 7) and
non-COPD patients (n = 9) were unstimulated (control) or challenged
with ω-6 PUFA arachidonic acid (AA) in 0.1% BSA-DMEM (100 μM)
for 48 h. Cell free supernatants were collected and cell viability was
estimated using lactate dehydrogenase (LDH) activity assay. Data is
expressed as the absorbance (OD) at 490 nm ± standard error of the
mean. Two-way ANOVA with Bonferroni post-hoc testing was used
to determine statistical significance. There were no statistical differences
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collagen in non-COPD cells (n = 5, p < 0.05). Challenge
with DHA or PA did not affect ECM protein expression
(data not shown) in COPD and non-COPD cells.
As mRNA levels do not always reflect corresponding
protein levels, the deposition of ECM proteins upon
challenge with AA 100 μM were also measured using
ECM ELISA. Challenge with AA (100 μM) resulted in a
reduced basal deposition of all ECM proteins measured
(fibronectin, tenascin, type I collagen and perlecan) in
COPD fibroblasts (n = 5–7) (p < 0.05). In non-COPD fi-
broblasts (n = 4–6) challenge with AA reduced the basal
deposition of perlecan and type I collagen (p < 0.05), but
not fibronectin or tenascin (Fig. 8).
Discussion
This study explored the relationship between dietary
fatty acids and airway inflammation and remodelling in
COPD using human pulmonary fibroblasts. We found
that the ω-6 PUFA AA causes substantial CXCL8 and
IL-6 release, and interestingly, this was impaired in fi-
broblasts from COPD patients. ω-3 PUFAs or SFAs did
not induce inflammatory responses in pulmonary fibro-
blasts from either group.
Pulmonary fibroblasts are the major structural cell of
the airway and are found at the interface of the lumen
and the blood supply and, therefore, they are directly ex-
posed to components of blood, including nutrients.
These cells play a crucial role in tissue homeostasis and
the production of pro-inflammatory cytokines and ECM
proteins, and, therefore are likely to contribute to airway
inflammation and remodelling in COPD [25, 26].
Typically, Western diets are deficient in ω-3 PUFAs
and contain excessive amounts of ω-6 PUFAs and SFAs.
ω-6 PUFAs and SFAs have predominantly been associ-
ated with pro-inflammatory effects, whereas the ω-3
PUFAs are predominantly anti-inflammatory [35]. West-
ern dietary patterns have been associated with an in-
creased risk of newly diagnosed COPD [36, 37] and with
greater lung function decline in COPD [38]. We found a
pro-inflammatory effect of AA, with impaired cytokine
release occurring in COPD cells.
Potential beneficial effects of ω-3 PUFAs have been
observed in many diseases, and there is some evidence
A B
Fig. 4 Similar cytokine release upon TNFα challenge in COPD versus non-COPD. Pulmonary fibroblasts from COPD (n = 15) and non-COPD
patients (n = 27) were unstimulated (control) or challenged with TNFα in 0.1% BSA-DMEM (1 ng/ml) for 48 h. Cell free supernatants were
collected and CXCL8 (a) and IL-6 (b) release was measured using ELISA. All data are represented as mean ± standard error of the mean. Two-way
ANOVA with Bonferroni post-hoc testing was used to determine statistical significance. There were no statistical differences
A B
Fig. 5 Dexamethasone suppresses AA-induced cytokine release in COPD and non-COPD. Pulmonary fibroblasts from COPD (n = 3) and non-COPD
(n = 6) patients were pre-treated with dexamethasone (0.001 - 1 μM) for 60 min prior to challenge with AA (100 μM) in 0.1% BSA-DMEM for 48 h.
Cell free supernatants were collected and CXCL8 (a) and IL-6 (b) release was measured using ELISA. All data are expressed as % of AA-induced
cytokine release ± standard error of the mean. Two-way ANOVA with Bonferroni post-hoc testing was used to determine statistical significance.
There were no statistical differences
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of a potential role in COPD [39, 40]. Several studies have
shown that ω-3 PUFAs reduce inflammation by inhibit-
ing TLR4 signalling [24]. In addition, observational stud-
ies have shown that diets rich in fruit, vegetables and
ω-3 PUFAs are positively associated with FEV1 and FVC
in the general population [41], and reduce the risk of
developing of COPD [36, 37, 42, 43]. We found no
pro-inflammatory effects of ω-3 PUFAs which is
consistent with most literature, however this study did
not investigate potential anti-inflammatory effects. Fur-
thermore, SFAs did not induce cytokine release from
pulmonary fibroblasts. SFAs, including PA, initiate in-
nate immune responses via TLR 2 and 4 signalling [44–
48]. The non-responsiveness to SFAs in this study may
be explained by the lack of functional TLR4/CD14 sig-
nalling in pulmonary fibroblasts [49, 50].
The majority of the patients in the COPD and
non-COPD group were smokers, however the percent-
age of smokers was higher in the COPD group. The
non-COPD group consists of patients with non-smoking
related end-stage lung diseases, as well as cells from
macroscopically normal lung tissue obtained from resec-
tion surgery. We confirmed that there was no difference
in the response to AA between these two groups. Fur-
thermore, TNFα induced similar cytokine release in the
COPD and non-COPD group. Taken together this shows
that COPD fibroblasts have a specific impairment in
their response to AA, independent of smoking history.
The current study measured IL-6 and CXCL8 as these
mediators are important in the pathogenesis of COPD
and are increased in serum and BAL fluid of COPD pa-
tients [15, 17]. IL-6 is a marker of systemic inflamma-
tion, a predictor of mortality and is negatively correlated
with lung function [15, 51]. CXCL8 is a potent neutro-
phil chemoattractant and activates neutrophils, leading
to the secretion of reactive oxygen metabolites, inflam-
matory cytokines and tissue damaging enzymes. In this
study AA induced lower levels of IL-6 and CXCL-8 in
COPD versus non-COPD pulmonary fibroblasts, sug-
gesting that in COPD meals rich in ω-6 PUFAs are not
as potent in the induction of inflammatory responses
compared to other chronic lung diseases.
AA affects inflammation through TLR4 independent
mechanisms. It acts as a bio-active molecule and is
converted into eicosanoids, including prostaglandins,
through metabolism by COX. Prostaglandins are known
a
b
Fig. 6 No correlation between BMI and arachidonic acid induced-
CXCL8 and IL-6 release. Body mass index (BMI) was correlated with
CXCL8 (a) and IL-6 (b) release upon challenge with arachidonic acid
(AA) (100 μM), in fibroblasts from both COPD (n = 18) and
non-COPD patients (n = 32). The correlation coefficient (r) was
determined using linear regression (Pearson analysis). There were
no correlations between BMI and CXCL8 or IL-6 release
A B C
Fig. 7 Reduced basal fibronectin and type I collagen expression upon arachidonic acid challenge. Pulmonary fibroblasts from COPD patients (n = 5)
and non-COPD (n = 3–4) were unstimulated (control) or challenged with the ω-6 PUFA arachidonic acid (AA) in 0.1% BSA-DMEM (10 and 100 μM) for
48 h. Total RNA was collected and fibronectin (a), Type I collagen (1A2) (b) and tenascin (c) were detected using real time PCR array. The results are
normalized to the endogenous control (18S rRNA), and presented as fold change from control ± standard error of the mean. Challenge with AA is
compared to control using a Two-way ANOVA with LSD fisher’s test. Significance is represented as * (p < 0.05) and ** (p < 0.01)
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to play a key role in the generation of inflammatory re-
sponses [52] and have been shown to affect cytokine
production in immune and lung cells [53, 54]. AA in-
duced prostaglandin E2 (PGE2) release, but there was no
difference between COPD and non-COPD fibroblasts.
The non-selective COX-inhibitor, indomethacin, and the
COX-2 selective inhibitor, celecoxib both partially sup-
pressed AA-induced IL-6 and CXCL8 release showing
that cytokine induction also occurs via COX-2 inde-
pendent mechanisms. There were no differences in the
percentage of inhibition between COPD and non-COPD
fibroblasts. In addition, there were no differences in
AA-induced COX-2 mRNA expression between COPD
and non-COPD cells.
Since BMI is associated with clinical outcomes in
COPD, we investigated whether obesity itself affects the
response to AA in pulmonary fibroblasts. We found no
effect of BMI on AA-induced CXCL8 or IL-6 release
from pulmonary fibroblasts, in both groups. Epidemio-
logical studies have reported that moderate obesity in
moderate to severe COPD has protective effects on sur-
vival, lung function decline and exacerbations [5–8]. Cai
et al. (2003) showed beneficial effects of high fat diet
versus low fat diet on lung function in COPD. These ef-
fects of obesity are contradictory to the known deleteri-
ous effects of obesity in the general population and
other diseases [55]. McDonald et al. (2016) investigated
the effect of exercise and a low-energy diet in obese
COPD patients. They found some clinically significant
improvements on COPD outcomes including health sta-
tus, but no effects on inflammatory markers and lung
function [56]. Clearly, more studies are needed to under-
stand the effects of obesity and diet in COPD.
We investigated the ability of dietary fatty acids to
affect ECM protein mRNA expression and deposition.
AA, but not DHA or PA reduced basal fibronectin and
type I collagen mRNA expression and fibronectin, type I
collagen, tenascin and perlecan deposition in COPD
fibroblasts. The inhibitory effect of AA on ECM protein
expression and deposition was less substantial in
non-COPD cells.
Fibronectin and tenascin are increased in COPD air-
ways and their presence is correlated with airway remod-
elling and/or inflammation and is negatively correlated
with FEV1 [11, 57, 58]. The effect of obesity on airway
remodelling is not well established. However, BMI has
been negatively associated with the severity of emphy-
sema, independent of gender, age and smoking history
and positively associated with airway wall thickness [12].
Our results show that AA suppresses the basal depos-
ition of fibronectin, type I collagen, tenascin and




Fig. 8 Reduced basal fibronectin, type I collagen, tenascin and perlecan deposition upon arachidonic acid challenge. Pulmonary fibroblasts from
COPD (n = 5–6) and non-COPD patients (n = 4–5) were unstimulated (control) or challenged with the ω-6 PUFA arachidonic acid (AA) in 0.1%
BSA-DMEM (100 μM) for 72 h. Deposition of fibronectin (a), type I collagen (b), tenascin (c) and perlecan (d) into the extracellular matrix (ECM)
was measured by ECM ELISA. All data are expressed at fold change compared to control ± standard error of the mean. Challenge with AA is
compared to control using a Two-way ANOVA with LSD fisher’s test. Significance is represented as * (p < 0.05), ** (p < 0.01), *** (p < 0.001) or
**** (p < 0.0001)
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factors could play a role in the regulation of ECM de-
position in COPD. ECM proteins play an essential role
in maintaining tissue homeostasis affecting many cellular
processes including proliferation, migration and repair
[59]. Decreased levels of ECM proteins could lead to in-
adequate repair mechanisms in COPD.
One limitation of our study is the lack of pulmonary
fibroblasts from obese and severely obese COPD and
non-COPD patients. In addition, the BMI was lower in
the COPD group compared to the non-COPD group.
This occurred by chance, as we did not select patients
on the basis of BMI; rather we used samples as they
were available. It may be that the protective effects of
obesity account for the lack of samples from the obese
COPD population, as if patients have reduced severity of
COPD they would not need lung transplantation. Inter-
estingly, a recent meta-analysis has shown that BMI is
also inversely associated with lung cancer [60], which
could explain the limited resection samples from obese
patients with a thoracic malignancy.
Conclusion
Our study demonstrates that ω-6 PUFA AA, but not ω-3
PUFA DHA or SFA PA, affects inflammatory processes
and ECM deposition in COPD. We found that whilst
AA increases inflammation, pulmonary fibroblasts from
patients with COPD had a reduced response to AA in
comparison to cells from people without COPD. Obesity
itself was not associated with the inflammatory response.
Moreover, we found that AA had a more substantial in-
hibitory effect on basal ECM-protein expression and de-
position in COPD cells compared to non-COPD cells.
This study suggest that the dietary fatty acid AA and
possibly other dietary components have disease-specific
effects and could explain differential effects of high fat
diets in different lung diseases. The impaired response
to AA in COPD might in part explain why obesity ap-
pears to have less detrimental effects in COPD, com-
pared to other lung diseases.
Additional file
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